News | May 20, 2013

Medicare Establishes Billing Code for InSightec's MR-Guided Focused Ultrasound

Therapy treats pain palliation of bone metastases

 

May 20, 2013 — InSightec Ltd. announced that the U.S. Centers for Medicare & Medicaid Services (CMS), a federal agency within the U.S. Department of Health and Human Services (HHS), has created a new billing code for magnetic resonance (MR) guided focused ultrasound treatment of pain palliation of metastatic bone lesions and has established a Medicare payment rate for hospital outpatient departments.

InSightec's ExAblate received U.S. Food and Drug Administration (FDA) approval for pain palliation of metastatic bone lesions in October 2012 and is the only MRgFUS system that is FDA approved for this indication. The approval was based on a two-arm randomized controlled trial comparing patients undergoing ExAblate MRgFUS for palliation of painful bone metastases with patients undergoing a placebo treatment.

ExAblate combines therapeutic acoustic ultrasound waves and continuous guidance and treatment monitoring with magnetic resonance imaging (MRI). Physicians use the MRI to plan and guide the therapy and monitor treatment outcome. The focused ultrasound acoustic energy destroys the nerves causing the pain, resulting in rapid pain reduction.

According to the American Cancer Society, more than two-thirds of metastatic breast and prostate cancers and up to 30 percent of metastatic lung, bladder and thyroid cancers spread to the bones. Close to 30 percent of patients with bone metastases either do not respond to radiation therapy or will be unable to undergo radiation for pain relief. ExAblate provides a single session, non-invasive option that is highly effective with a low complication rates.

"We are extremely pleased with CMS' decision to provide a code and establish payment for MR guided focused ultrasound for bone metastases," said Kobi (Jackob) Vortman, president and chief executive officer of InSightec. "This is particularly important for the many cancer patients with crippling bone pain who are no longer eligible for radiation treatment. ExAblate is a safe and effective adjunctive treatment which enables patients to more quickly reduce their pain and their reliance on narcotic pain medications."

The new code, C9734, became effective April 1, 2013, and it was assigned to Ambulatory Payment Classification (APC) group 0067 (Level III Stereotactic Radiosurgery, MRgFUS and MEG).

ExAblate is the only MRgFUS system with FDA approval for pain palliation of bone metastases and for uterine fibroids. In addition, it has received European CE marking for uterine fibroids, bone metastases, benign bone tumors, adenomyosis, essential tremor, tremor-dominant Parkinson's disease and neuropathic pain. FDA approved clinical trials are ongoing for essential tremor, Parkinson's disease and prostate cancer.

For more information: us.insightec.com

Related Content

LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
SyMRI Software Receives FDA Clearance for Use With Siemens MRI Systems
Technology | Magnetic Resonance Imaging (MRI) | June 14, 2019
SyntheticMR announced U.S. Food and Drug Administration (FDA) clearance for clinical use of its SyMRI Image and SyMRI...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
Ann Arbor Startup Launches Augmented Reality MRI Simulator
Technology | Virtual and Augmented Reality | June 04, 2019
SpellBound, an Ann Arbor startup specializing in augmented reality (AR) tools for children in hospitals, has officially...

Photo courtesy of Philips Healthcare

Feature | Radiology Business | May 31, 2019 | By Arjen Radder
Change is a consistent theme in our world today, no matter where you look.
MRI Metal Artifact Reduction Poses Minimal Thermal Risk to Hip Arthroplasty Implants
News | Magnetic Resonance Imaging (MRI) | May 23, 2019
Clinical metal artifact reduction sequence (MARS) magnetic resonance imaging (MRI) protocols at 3 Tesla (3T) on hip...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...